Fitness News
 > Asthma Allergy News
Diabetes News
Women's Health News
Men's Health News

Personal Archive
My Account

About Us
Advertise With Us
Feed Your Site
Contact Us

Site Map
RSS News Feed 

  Website development & hosting
   by Cyber Software Solutions

Long-Acting Bronchodilators Up Cardiovascular Risk in COPD
Findings among older adults newly prescribed long-acting β-agonists or anticholinergics

THURSDAY, May 23 (HealthDay News) -- New use of either long-acting β-agonists or anticholinergics is associated with increased risks of cardiovascular events among older individuals with chronic obstructive pulmonary disease (COPD), according to a study published online May 20 in JAMA Internal Medicine.

Andrea Gershon, M.D., from the Institute for Clinical Evaluative Sciences in Canada, and colleagues conducted a nested case-control analysis involving 191,1005 eligible patients aged 66 years and older being treated for COPD. The risk of cardiovascular events was compared for patients newly prescribed inhaled long-acting β-agonists and anticholinergics and matched patients not using these medications.

The researchers found that 28.0 percent of patients had a hospitalization or emergency department visit for a cardiovascular event. The risk of an event was significantly higher among those newly prescribed long-acting inhaled β-agonists and anticholinergics than among those not using those medications (respective adjusted odds ratios, 1.31 and 1.14). There was no significant difference in events when comparing β-agonists and anticholinergics (adjusted odds ratio, 1.15; P = 0.16).

"Among older individuals with COPD, new use of long-acting β-agonists and anticholinergics is associated with similar increased risks of cardiovascular events," the authors write. "Close monitoring of COPD patients requiring long-acting bronchodilators is needed regardless of drug class."

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Health News Copyright © 2013 HealthDay. All rights reserved.

Back to Top Stories